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Abstract: Developmental studies indicate the Wnt/ -catenin pathway biphasically regulates tissue differentiation.
Bone morphogenetic protein (BMP) and Wnt signaling reported function in osteoblast differentiation, but few
studies have investigated these complex mechanisms. We hypothesized that Wnt/ -catenin signaling acts, either
promoting or inhibiting osteogenesis of human periodontal ligament (HPDL) cells depending on times of
treatment of Wnt3A. HPDL cells were treated with single or repeated administration (12- or 24-h intervals) of
10 ng/ml of Wnt3A and cultured for 3 days. Single Wnt3A administration increased alkaline phosphatase
(ALP) activity. Conversely, repeated Wnt3A administration significantly decreased the expression of osteoblast
marker genes. Single Wnt3A administration resulted in Smad1/5 and Akt phosphorylation; however, repeated
Wnt3A administration inhibited it. BMP2/7 or IGF-1 treatment was sufficient to reverse the inhibitory effects
of repeated Wnt3A treatment. Single administration of a glycogen synthase kinase 3 inhibitors, CHIR99021,
increased ALP expression, but repeated CHIR99021 administration significantly decreased ALP expression
and ALP activity compared with single administration. These findings suggest that repeated activation of Wnt
signaling inhibits osteoblast differentiation by suppressing the BMP2/7–Smad1/5 and phosphatidylinositide 3-
kinase (PI3K) /Akt pathways in HPDL cells. This indicated that crosstalk between the Wnt, Smad1/5, and
PI3K/Akt pathways is important for osteoblastic differentiation of HPDL cells.
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Introduction
The human periodontal ligament (HPDL) cells exhibit the
potential to differentiate into cells of multiple lineages, including
osteoblasts, in vitro1,2), and provide the machinery to regenerate
periodontal tissues, including alveolar bone, whereas growth
factors such as cytokines found in periodontal tissues modulate
cellular activities and induce cell differentiation. We previously
reported an experimental model that allows the investigation of
inhibitory effects of transforming growth factor- 1 (TGF- 1) on
osteoblast differentiation and found that repeated or high-dose
administration of TGF- 1 inhibited osteoblast differentiation of
HPDL cells by decreasing insulin-like growth factor-1 (IGF-1)
expression and subsequently downregulating phosphatidylinositide
3-kinase (PI3K)/Akt signaling3,4). However, many aspects of the
mechanisms by which HPDL cells differentiate into osteoblasts
remain unclear.
Wnt signaling is a critical regulator of skeletal physiology.
Wnt signaling activation enhances osteoblastogenesis and
suppresses adipogenesis by inhibiting peroxisome proliferator-
activated receptor (PPAR )5). Wnt signaling draw many attentions
recently,because neutralizing antibodies against Wnt antagonists
are promising new drugs for bone diseases. But recent evidences
indicated that Wnt signaling exerts a pivotal biphasic and dosage-
dependent regulation of osteoclastogenesis6, 7). Therefore, although
Wnt signaling is known as potent enhancer of osteoblast
differentiations, these eviedences still indicate that Wnt signaling
might have biphasic function in osteoblast differentiations. Based
on these facts and our previous results, we hypothesized that
Wnt3A might have biphasically effects on osteoblastic
differentiation of HPDL cells like our reported of TGF- 1.
Wnt signaling plays essential roles in osteogenesis by directly
stimulating runt-related transcription factor 2 (RUNX2) gene
expression, promoting osteogenesis8). Recently, a previous study
involving the knockout of inhibitors of Wnt signaling revealed
the importance of Wnt signaling in bone formation and
metabolism9). The sclerostin (SOST) gene encodes the SOST
protein, which antagonizes Wnts by binding to LRP5/6 identically
to Dkk1; SOST mutations prevent osteocytes from secreting
sufficient levels of fully functional SOST10). The bone-generating
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Table 1. Primers used for quantitative real time PCR
Gene symbol GenBankTM          Primsequence:sense/antisense         Probe no.      Amplicon
accession no.
RUNX2 NM_001024630.2           5'-gtgcctaggcgcatttca-3'                     #29              78bp
           5'-gctcttcttactgagagtggaagg-3'
ALP             NM_000478.3            5'-caaccctggggaggagac-3'                  #19               78bp
           5'-gcattggtgttgtacgtcttg-3'
BSP             NM_004967.3            5'-caatctgtgccactcactgc-3'                  #38              74bp
            5'-tcattttggtgattgcttcct-3'
COL1A1 NM-000088.3            5'-gggattccctggacctaaag-3'                #67               63bp
           5'-ggaaacctcgctctcca-3'
IGF-1 NM_000618.3            5'-tgtggagacaggggctttta-3'                 #67               84bp
           5'-atccacgatgcctgtctga-3'
MSX-2 NM_002449.4            5'-tcggaaaattcagaagatgga-3'               #70              86bp
           5'-caggtggtagggctcatatgtc-3'
18 S rRNA              M11188.1            5'-cggacaggattgacagattg-3'                #77              78bp
           5'-cgctccaccaactaagaacg-3'
effects of targeting functional antagonists of Wnt signaling have
yielded new therapeutic tools to neutralize Wnt antagonists for
the treatment of selected bone diseases and skeletal conditions.
Wnt3A is a major activator of the canonical Wnt pathway11).
Wnt3a is involved in bone formation and maintenance during
growth and in the adult skeleton, and it reportedly plays an
important role in the metabolism of bone mass12-14). However,
crosstalk between canonical Wnt signaling and other known
regulators of osteogenesis such as the Bone morphogenetic protein
(BMP)/Smad and PI3K/Akt, is only undergoing investigation15-
19). In a recent report, genetic ablation of a BMP receptor was
unexpectedly shown to enhance osteogenesis by downregulating
Wnt antagonists20). In this study, we show that repeated Wnt3A
treatment negatively regulates the osteoblastic differentiation of
HPDL cells. We found that BMP2/7 or IGF-1 effectively
compensate for the inhibitory effects of repeated Wnt3A treatment.
Interestingly, IGF-1 exhibited a more potent compensatory effect.
Furthermore, our results suggested that the BMP/Smad and PI3K/
Akt pathways play important roles in Wnt3A signaling in HPDL
cells and during their early-phase osteoblastic differentiation.
Materials and Methods
Cell culture and osteogenic differentiation
Normal HPDL cells were purchased from Lonza Group AG
(Basel, Switzerland) and cultured in BulletKit™ Stromal Cell
Growth Medium (Lonza Group AG). HPDL Cells at passages 5–
8 were seeded at a density of 1 × 105 cells/cm2 in -minimum
essential medium ( -MEM; Invitrogen, Carlsbad, CA, USA), with
or without 10 ng/ml of rhWnt3A (R&D Systems, Minneapolis,
MN, USA) added the following day. Some cells were treated with
3- M CHIR99021 (R&D Systems), a GSK3  inhibitor. Some cells
were also treated with 200 ng/ml IGF-1 (Wako Pure Chemical
Industries, Ltd.) or 100 ng/ml BMP2/7 (R&D Systems). In the
repeated administration group, the medium was replaced with fresh
-MEM containing Wnt3A or Wnt3A and IGF-1 or Wnt3A and
BMP2/7, every 12 or 24 h, for 3 days. Control cells were cultured
in -MEM.
ALP activity assay
Three days after stimulation, cells were washed two times with
phosphate-buffered saline (Invitrogen), fixed with 4 %
paraformaldehyde for 5 min at room temperature, and washed
three times with distilled water. For staining, an ALP substrate
solution (Roche Diagnostics, Basel, Switzerland) was added to
the fixed cells for 60 min at room temperature. After staining,
cells were washed three times with distilled water, and images
were analyzed.
Real-time reverse transcription-polymerase chain reaction
Total cellular RNA was extracted using QIAzol® Lysis Reagent
(Qiagen NV, Venlo, Limburg, The Netherlands) according to the
manufacturer’s instructions. cDNA was synthesized using a High-
Capacity cDNA Reverse Transcription Kit (Applied Biosystems,
Inc., Foster City, CA, USA). Real-time reverse transcription-
polymerase chain reaction (rRT-PCR) was performed on a 7500
Real-Time PCR System (Applied Biosystems, Inc.) using the
Premix Ex Taq™ reagent (Takara Bio Inc., Shiga, Japan). The
target genes were ALP, bone sialoprotein (BSP), IGF-1, RUNX2,
msh homeobox 2 (MSX2), and collagen type I alpha 1 (COL1A1).
All primers and probes are presented in Table 1 and were designed
using Probefinder (http://qpcr.probefinder.com/organism.jsp). The
expression of each gene was normalized to that of 18S rRNA.
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Figure 1. Single Wnt3A administration activates alkaline phosphatase
expression in a concentration-dependent manner in HPDL cells.
(A) mRNA expression levels of ALP in HPDL cells, treated with a
single administration of 1, or 10 ng/ml of Wnt3A and cultured in α-
MEM for 3 days, were examined by rRT-PCR. (n = 4). (**P < 0.01, *P
< 0.05). (B) ALP activity assay of single or repeated administration of
Wnt3A and untreated (Control). (C) mRNA expression levels of ALP
treated with single or repeated administration of Wnt3A were examined
by rRT-PCR. (n = 5). (**P < 0.01, *P < 0.05).
The relative expressions of genes of interest were estimated by
the     Ct method. Each experiment was performed in triplicate,
and the data represent the means ± standard deviation (**P <
0.01, *P < 0.05).
Protein extraction and immunoblotting
Cells were lysed in lysis buffer [10-mM Tris-HCl (pH 7.5),
150-mM NaCl, complete protease inhibitor mixture, 1-mM
sodium orthovanadate, and 1 % Nonidet P-40], and protein
concentrations were measured using the DC™ Protein Assay Kit
(Bio-Rad Laboratories, Inc., Hercules, CA, USA). Equivalent
amounts of protein were separated by electrophoresis on
NuPAGE® 4 %–12 % Bis-Tris gels (Invitrogen) and transferred
on to polyvinylidene difluoride membranes. Membranes were
probed with anti-Akt/anti-phosphorylated Akt (1:1000; Cell
Signaling Technology, Inc., Danvers, MA, USA) and anti-Smad1/
anti-phosphorylated Smad1/5 (1:1000; Cell Signaling Technology,
Inc.) antibodies, followed by horseradish peroxidase-conjugated
goat anti-rabbit Immunoglobulin G antibody (MP Biomedicals,
Illkirch-Graffenstaden, France). Bound antibodies were visualized
using a chemiluminescent substrate (ECL™ Prime Western
Blotting Detection Reagent; GE Healthcare, Little Chalfont,
Buckinghamshire, UK) and ImageQuant LAS 4000 Mini (GE
Healthcare).
Statistical analysis
     Each experiment was repeated three times. All data are
expressed as means ±standard error of the mean. Differences were
assessed using the Kruskal–Wallis test with the Tukey–Kramer
post-hoc test.
Results
ALP expression of HPDL cells following Wnt3A treatment
Single Wnt3A treatment (1 or 10 ng/ml) increased ALP
expression in HPDL cells cultured in α-MEM in a dose-responsive
manner (Fig. 1A).
Repeated Wnt3A administration inhibits ALP activity of HPDL
cells
Single administration of 10 ng/ml of Wnt3A increased ALP
activity significantly, as assessed by ALP cell staining (Fig. 1B).
Conversely, repeated Wnt3A administration decreased ALP
activity (Fig. 1B). ALP activity exhibited by cells decreased as
the number of Wnt3A treatments increased. Single Wnt3A
administration increased ALP expression; however, repeated
Wnt3A administration reduced ALP expression by almost 90 %
in HPDL cells (Fig. 1C).
Expressions of osteoblast markers and related genes in HPDL
cells
As shown in Fig. 2A-E, repeated Wnt3A administration caused
a significant decrease in the expressions of osteoblast
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Figure 2. Repeated Wnt3A administration decreases the expression
of osteogenic differentiation-related genes and inhibits Smad1/5 and
Akt phosphorylation in HPDL cells. (A-E) mRNA expression levels
of the osteogenic differentiation-related genes bone sialoprotein (A),
insulin-like growth factor-1 (IGF-1; B), runt-related transcription
factor 2 (C), msh homeobox 2 (D), and collagen type I alpha 1 (E) in
HPDL cells treated with single or repeated administration of Wnt3A
were examined by rRT-PCR. (n = 5). (**P < 0.01, *P < 0.05). (F)
Western blot t ing analysis revealed the inhibi t ion of Akt
phosphorylation by repeated administration of Wnt3A. Total Akt was
detected as a control. (G) Western blotting analysis revealed that
Smad1/5 phosphorylation was inhibited by repeated administration
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differentiation-related genes (BSP, IGF-1, and RUNX2).
Expression of MSX2, which is known to regulate osteoblast
differentiation under the control of BMP2, also significantly
decreased following repeated Wnt3A administration. We observed
no significant difference in COL1A1 expression following single
and repeated Wnt3A administrations (Fig. 2E).
Effect of repeated Wnt3A administration on the Smad and PI3K/
Akt pathways in HPDL cells
Previously, we reported that repeated TGF-β1 treatment
reduced IGF-1 secretion, which subsequently downregulated PI3K
signaling3). We examined whether the inhibitory effects caused
by repeated Wnt3A treatment were reversed by IGF-1
administration. Next we investigated Akt activation and found
that repeated Wnt3A treatment significantly reduced Akt
phosphorylation (Fig. 2F). Because BMP2 reportedly regulates
osteoblast differentiation through MSX-2 and RUNX2, we
examined BMP/Smad1/5 activation21). Repeated Wnt3A
administration inhibited phosphorylation of Smad1/5 (Fig. 2G).
In controls, we observed normal phosphorylation of Smad1/5 and
Akt (Fig. 2F and G).
Exogenous IGF-1 and BMP2/7 reversed the inhibition of
osteogenic differentiation by repeated Wnt3A administration
The 100-ng/ml BMP2/7 treatment significantly induced ALP
expression even with the repeated Wnt3A administration (Fig.
3A). The reversal also caused increased ALP expression in the
IGF-1 addition group (Fig. 3A) and was accompanied by increased
Akt phosphorylation (Fig. 3D). We observed significant difference
in RUNX2 expression when cells were treated with Wnt3A and
BMP2/7 repeatedly (Fig. 3B). Exogenous IGF-1 treatment
significantly increased RUNX2 expression (Fig, 3B). Exogenous
Figure 3. Exogenous IGF-1 and BMP2/7 reversed the inhibition of osteogenic differentiation by repeated Wnt3A administration. (A) mRNA
expression levels of ALP treated with repeated administration of Wnt3A and IGF-1, or repeated administrations of Wnt3A and BMP2/7 were
examined by rRT-PCR. (n = 5). (**P < 0.01, *P < 0.05). (B and C) mRNA expression levels of the osteogenic differentiation-related genes
RUNX2 (B) and MSX-2 (C) in HPDL cells were examined by rRT-PCR (n = 5). (**P < 0.01). (D) Western blotting analysis revealed that the
inhibition of Akt phosphorylation caused by repeated Wnt3A administration was reversed by IGF-1. Total Akt was detected as a control.
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BMP2/7 significantly increased MSX2 expression (Fig. 3C).
Effect of CHIR99021 administration on the expressions of
osteoblast markers and differentiation-related genes in HPDL
cells
We investigated the effects of single or repeated administration
of CHIR99021, a specific GSK3β inhibitor, on osteoblast
differentiation of HPDL cells. GSK3β is an inhibitor of β-catenin
translocation into the nucleus; therefore, CHIR99021
administration activates the canonical Wnt/β-catenin pathway.
Single CHIR99021 administration increased ALP activity and
expression (Fig. 4A and B). Repeated CHIR99021 administration
significantly decreased ALP activity and expression, as evident
after repeated Wnt 3A administration (Fig. 4A and B). Repeated
CHIR99021 administration every 24 h significantly decreased
MSX2  expression compared with single CHIR99021
administration (Fig. 4C).
Discussion
In this study, we report two important findings. First, repeated
Wnt3A treatment downregulates ALP expression and early-phase
osteoblast differentiation of HPDL cells. Previously, we reported
that repeated TGF-β1 treatment to HPDL cells downregulates ALP
expression4). We observed subsequent decreased IGF-1 expression
and inhibition of PI3K/Akt signaling3). In this study, we found
that repeated Wnt3A treatment caused both decreased IGF-1
expression and decreased Akt phosphorylation, also previously
observed following repeated TGF-β1 administration3).
Wnts trigger multiple signals essential for tissue regeneration
and embryonic development22). It is established that Wnt3A
functions in osteoblast differentiation23). As shown in Figure 1B,
single Wnt3A administration induced ALP activation in HPDL
cells. Wnts are essential during many stages of osteoblast lineage
development and maturation; however, their signaling
mechanisms are complex. Genetic analyses involving mutations
in Wnt receptors and their antagonists implicate Wnt signaling in
bone disease9). A fast-growing field of Wnt signaling implies
aberrant Wnt signaling underlies a wide range of bone diseases24).
Wnt3A and Wnt5A mutations are embryonic lethal; however,
heterozygous Wnt3A and Wnt5A mouse mutants exhibit decreased
bone mineral density25). Therefore, even marginal alterations in
the amplitude and duration of Wnt signaling affect skeletal
formation and bone remodeling13). Thus, prolonged activation of
Wnt signaling may cause biphasically effects through excessive
activation of feedback mechanisms.
We found that repeated Wnt3A administration could suppress
ALP expression (Fig. 1B and C), similar to repeated TGF-β1
administration, as we previously reported 4). Expressions of other
osteoblast markers and differentiation-related genes such as BSP,
IGF-1, RUNX2, and MSX2 are also decreased following repeated
Wnt3A administration (Fig. 2A-D). We found that repeated Wnt3A
administration remarkably decreased IGF-1 expression and,
consequently, Akt phosphorylation (Fig. 2B and F). IGF-1 plays
an important role in cell growth, differentiation, survival, cell
cycle progression and regulation of bone homeostasis26). IGF-1
knockout mice reportedly exhibit short-limb dwarfism, delays in
mineralization, and increased chondrocyte apoptosis27). Our recent
Figure 4. The effect of single or repeated CHIR99021 administration
on the osteogenic differentiation of HPDL cells. (A) ALP activity assay
of single or repeated administration of CHIR99021 and untreated
(Control). (B and C) mRNA expression levels of ALP (B) and MSX-2
(C) in HPDL cells treated with single or repeated administration of
CHIR99021 were examined by rRT-PCR (n = 5). (**P < 0.01).
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report revealed that the inhibition of autocrine IGF-1 expression
may inhibit osteogenic differentiation3). We found that repeated
Wnt3A administration suppressed both IGF-1 expression and Akt
phosphorylation, indicating the inhibition of the IGF-1/PI3K
pathway. However, exogenous IGF-1 reversed this inhibition,
suggesting that pathways downstream of IGF-1/PI3K signaling
were not blocked by repeated Wnt3A treatment.
Our second important finding was the importance of the BMP/
Smad pathway in Wnt signaling. Repeated Wnt3A treatment
decreased MSX2 expression (Fig. 2D). BMP2 reportedly induces
MSX2 and RUNX2, which in turn induce Osterix21). It is possible
that reduced MSX2 expression downregulates BMP signaling of
HPDL cells. Other indications of crosstalk between Wnt and BMP2
signaling are evident in BMP-receptor knockout mice. Osteoblast-
specific conditional knockout mice for BMP receptor type IA
reportedly exhibit increased bone mass during embryonic
development due to the suppression of the Wnt inhibitor SOST20).
These findings suggest that BMP2/7 treatment induces Wnt
inhibitors, enhancing the inhibition of osteoblast differentiation.
Contrary to our expectations, BMP2/7 could remarkably increase
ALP expression even following repeated Wnt3A treatment (Fig.
3A). We found that repeated Wnt3A treatment decreased Smad1/
5 phosphorylation (Fig. 2G). The addition of BMP2/7 to HPDL
cells undergoing repeated Wnt3A treatment significantly increased
MSX2 expression (Fig. 3C). These facts sugeested that prolonged
Wnt3A treatment causes downregulation of the BMP/Smad
cascade. It is established that the PI3K/Akt signaling pathway is
enhanced by DNA binding of Runx2 and Runx2-dependent
transcription28). Runx2 increases ALP activity, expression of BMP
genes, and mineralization in immature mesenchymal cells and
osteoblastic cells in vitro13,28-30). Thus, repeated Wnt3A treatment
coordinately inhibits the BMP and IGF-1/PI3K pathways.
According to these results, we speculated that repeated Wnt3A
administration would decrease the expression of MSX2, a direct
target of the Smad pathway, which in turn would inhibit early-
phase osteogenic differentiation of HPDL cells.
A previous study reported that CHIR99021, an inhibitor of
GSK3β, induced osteogenesis, as indicated by elevated ALP
activity, in ST2 mice mesenchymal cells31). Our results showed
that single CHIR99021 administration increased ALP activation
and expression, whereas repeated CHIR99021 administration
significantly decreased ALP activation and expression compared
with single CHIR99021 administration (Fig. 4A and B). In
addition, repeated CHIR99021 administration decreased MSX2
expression (Fig. 4C). A previous report showed that the inhibition
or stimulation of GSK3β activity resulted in induction or
suppression of ALP activity, respectively, through a GSK3β-
dependent mechanism32). Gsk3β knockout mice do not survive
embryogenesis; however, Gsk3β      mice exhibit higher trabecular
bone volume density, more osteoblasts per area of bone surface,
and increased bone formation rates33). These results are consistent
with those of previous studies showing decreased bone
mineralization in targeted heterozygous Wnt3A or Wnt5A mice25).
These biphasic function of Wnt signaling might have a clinical
significance, because Wnt activation is a promising therapeutic
strategy for treating bone diseases based on its currently known
bone formation-stimulating anabolic effects. For example, a
neutralizing monoclonal antibody (Ab) against the Wnt antagonist
sclerostin, which is secreted specifically from osteocytes34), has
been shown to markedly increase bone formation and reverse
estrogen deficiency-induced bone loss35). Currently, SOST-
antibody is being developed as a new anabolic treatment for bone
disorders, such as postmenopausal osteoporosis35). Other findings
provide evidences that Wnt activation also inhibits osteoclast
differentiation and bone resorption7). Consistent with this notion,
in a recent first-in-humans study, a sclerostin monoclonal antibody
not only increased bone formation marker but also decreased bone
resorption marker in a dose-dependent manner. Therefore, bone-
specific activators of Wnt/β-catenin signaling may promise an
exciting new class of drugs that can more effectively prevent and
treat skeletal fragility. But our evidences indicate that Wnt
signaling might not be that simple. Developmental studies indicate
that the Wnt canonical pathway biphasically regulates tissue
differentiation7). Even BMP2 pathway could negatively regulate
Wnt signaling by inducing SOST 20).
     In summary, it is possible that sufficient Wnt signaling is
required for proper osteoblast differentiation. Excess or insufficient
Wnt3A may inhibit osteoblast differentiation, i.e., alterations in
the intensity, amplitude, and duration of Wnt signaling affects the
osteogenesis of HPDL cells positively and negatively. There is a
great deal of complexity about bone remodeling, as detailed in
many reports and in the results of this study. Thus, further studies
are warranted to clarify its complicated mechanisms.
In conclusion, Wnt3A plays an important role of osteogenic
differentiation of HPDL cells by activation of not only Wnt
signaling but also of the Smad and PI3K/Akt pathways.
Conversely, repeated Wnt3A administration has a negative effect
on osteogenic differentiation of HPDL cells. This negative effect
of Wnt3A was reversed by IGF-1 or BMP2/7. Thus, crosstalk
between Wnt3A, IGF-1, and BMP2/7 signaling is necessary for
the regulation of osteoblast differentiation. We believe that a better
understanding of these complex mechanisms will lead to find new
way to study about the role of Wnt sgnaling in pathogenesis of
periodontal diseases and eventually will lead to find a new clue
for bone regeneration of periodontal tissues.
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